HERZLIYA, Israel and NEW YORK, Jan. 30, 2012 (GLOBE NEWSWIRE) -- IMMUNE Pharmaceuticals, an emerging leader in the development of monoclonal antibody based therapeutics for the treatment of inflammatory diseases and cancer, today announced that the Office of the Chief Scientist (OCS) granted US$1 million (NIS 3.8M) to support two drug development programs:
